These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 6796658

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
    Neuwelt EA, Hill SA, Frenkel EP, Diehl JT, Maravilla KR, Vu LH, Clark WK, Rapoport SI, Barnett PA, Lewis SE, Ehle AL, Beyer CW.
    Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification.
    Neuwelt EA, Pagel M, Barnett P, Glassberg M, Frenkel EP.
    Cancer Res; 1981 Nov; 41(11 Pt 1):4466-70. PubMed ID: 6796261
    [Abstract] [Full Text] [Related]

  • 9. Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain.
    Neuwelt EA, Barnett PA, McCormick CI, Frenkel EP, Minna JD.
    Neurosurgery; 1985 Sep; 17(3):419-23. PubMed ID: 3930991
    [Abstract] [Full Text] [Related]

  • 10. Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog.
    Neuwelt EA, Frenkel EP, Rapoport S, Barnett P.
    Neurosurgery; 1980 Jul; 7(1):36-43. PubMed ID: 6774280
    [Abstract] [Full Text] [Related]

  • 11. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
    Siegal T, Rubinstein R, Bokstein F, Schwartz A, Lossos A, Shalom E, Chisin R, Gomori JM.
    J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
    [Abstract] [Full Text] [Related]

  • 12. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats.
    Cosolo W, Christophidis N.
    Cancer Res; 1987 Dec 01; 47(23):6225-8. PubMed ID: 3119195
    [Abstract] [Full Text] [Related]

  • 13. Feasibility and Safety of Intra-arterial Pericyte Progenitor Cell Delivery Following Mannitol-Induced Transient Blood-Brain Barrier Opening in a Canine Model.
    Youn SW, Jung KH, Chu K, Lee JY, Lee ST, Bahn JJ, Park DK, Yu JS, Kim SY, Kim M, Lee SK, Han MH, Roh JK.
    Cell Transplant; 2015 Dec 01; 24(8):1469-79. PubMed ID: 24932854
    [Abstract] [Full Text] [Related]

  • 14. Enhanced disruption of the blood brain barrier by intracarotid mannitol injection during transient cerebral hypoperfusion in rabbits.
    Wang M, Etu J, Joshi S.
    J Neurosurg Anesthesiol; 2007 Oct 01; 19(4):249-56. PubMed ID: 17893577
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
    Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T.
    Clin Pharmacol Ther; 2000 Jun 01; 67(6):631-41. PubMed ID: 10872645
    [Abstract] [Full Text] [Related]

  • 16. Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies.
    Neuwelt EA, Glasberg M, Frenkel E, Barnett P.
    Ann Neurol; 1983 Sep 01; 14(3):316-24. PubMed ID: 6195955
    [Abstract] [Full Text] [Related]

  • 17. Technique of, and complications attributable to, repeated hyperosmotic blood-brain barrier disruption in dogs.
    Culver B, Inzana K, Jones J, Troy G, Kroll R, Culver B, Jortner B.
    Am J Vet Res; 1998 Nov 01; 59(11):1503-10. PubMed ID: 9829415
    [Abstract] [Full Text] [Related]

  • 18. Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening.
    Neuwelt EA, Balaban E, Diehl J, Hill S, Frenkel E.
    Neurosurgery; 1983 Jun 01; 12(6):662-71. PubMed ID: 6410302
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The effects of the Na(+)/Ca(++) exchange blocker on osmotic blood-brain barrier disruption.
    Bhattacharjee AK, Nagashima T, Kondoh T, Tamaki N.
    Brain Res; 2001 May 11; 900(2):157-62. PubMed ID: 11334793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.